Prism Medico & Pharmacy Ltd
₹ 21.0
4.17%
21 Oct
- close price
About
Incorporated in 1985, Prism Medico and Pharmacy Ltd is in the business of Wholesale and Retail of straw, fodder and other animal/ poultry feed[1]
Key Points
- Market Cap ₹ 12.7 Cr.
- Current Price ₹ 21.0
- High / Low ₹ 29.2 / 11.6
- Stock P/E 18.2
- Book Value ₹ 24.9
- Dividend Yield 0.00 %
- ROCE -0.40 %
- ROE -0.33 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Stock is trading at 0.84 times its book value
Cons
- The company has delivered a poor sales growth of -52.8% over past five years.
- Promoter holding is low: 25.0%
- Company has a low return on equity of -0.34% over last 3 years.
- Company has high debtors of 2,074 days.
- Working capital days have increased from 4,885 days to 8,551 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.09 | 0.09 | 20.96 | 36.31 | 26.89 | 16.76 | 8.44 | 1.27 | 2.93 | 0.63 | 2.16 | |
| 0.05 | 0.06 | 0.15 | 0.37 | 20.86 | 35.98 | 26.94 | 16.92 | 8.93 | 1.37 | 3.06 | 0.71 | 1.50 | |
| Operating Profit | -0.05 | -0.06 | -0.06 | -0.28 | 0.10 | 0.33 | -0.05 | -0.16 | -0.49 | -0.10 | -0.13 | -0.08 | 0.66 |
| OPM % | -66.67% | -311.11% | 0.48% | 0.91% | -0.19% | -0.95% | -5.81% | -7.87% | -4.44% | -12.70% | 30.56% | ||
| 0.00 | 0.06 | 0.06 | 0.07 | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.02 | 0.01 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.01 | 0.01 | 0.02 | 0.04 | 0.03 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Profit before tax | -0.05 | -0.01 | -0.01 | -0.23 | 0.05 | 0.29 | -0.07 | -0.17 | -0.50 | -0.11 | -0.03 | -0.06 | 0.67 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 140.00% | -24.14% | -28.57% | -29.41% | -26.00% | -27.27% | -33.33% | -33.33% | |
| -0.05 | -0.01 | -0.01 | -0.23 | -0.02 | 0.37 | -0.05 | -0.13 | -0.37 | -0.08 | -0.02 | -0.05 | 0.70 | |
| EPS in Rs | -0.25 | -0.05 | -0.05 | -0.38 | -0.03 | 0.61 | -0.08 | -0.21 | -0.61 | -0.13 | -0.03 | -0.08 | 1.16 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -53% |
| 3 Years: | -58% |
| TTM: | -28% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 0% |
| 3 Years: | 23% |
| TTM: | 3600% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 0% |
| 3 Years: | 20% |
| 1 Year: | -24% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | -1% |
| 3 Years: | 0% |
| Last Year: | 0% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 1.99 | 1.99 | 1.99 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 | 6.06 |
| Reserves | -0.35 | -0.36 | -0.36 | 6.74 | 6.72 | 7.09 | 6.99 | 6.86 | 6.49 | 9.10 | 9.08 | 9.03 |
| 0.00 | 0.02 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.02 | 0.04 | 0.16 | 0.25 | 0.16 | 3.82 | 8.54 | 8.63 | 0.02 | 0.23 | 0.10 | 0.47 | |
| Total Liabilities | 1.66 | 1.69 | 1.86 | 13.05 | 12.94 | 16.97 | 21.59 | 21.55 | 12.57 | 15.39 | 15.24 | 15.56 |
| 0.02 | 0.01 | 0.00 | 0.16 | 0.11 | 0.09 | 0.07 | 0.06 | 0.05 | 0.03 | 0.03 | 0.03 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 10.00 | 11.25 | 10.00 | 1.94 | 1.94 | 0.00 | 0.00 | 0.00 | 0.00 |
| 1.64 | 1.68 | 1.86 | 2.89 | 1.58 | 6.88 | 19.58 | 19.55 | 12.52 | 15.36 | 15.21 | 15.53 | |
| Total Assets | 1.66 | 1.69 | 1.86 | 13.05 | 12.94 | 16.97 | 21.59 | 21.55 | 12.57 | 15.39 | 15.24 | 15.56 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.04 | 0.01 | 0.05 | -0.82 | -0.06 | -1.23 | -4.36 | -0.05 | -2.38 | 2.95 | -0.01 | -0.02 | |
| 0.03 | 0.00 | 0.46 | 0.30 | -1.25 | 1.25 | 4.36 | 0.02 | 2.35 | -2.91 | 0.00 | 0.00 | |
| 0.00 | 0.02 | 0.05 | 1.33 | -0.05 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | |
| Net Cash Flow | 0.00 | 0.02 | 0.56 | 0.81 | -1.36 | 0.08 | -0.01 | -0.03 | -0.03 | 0.04 | -0.01 | -0.02 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365.00 | 0.00 | 0.00 | 37.80 | 248.94 | 294.22 | 211.04 | 1,368.03 | 459.68 | 2,074.13 | ||
| Inventory Days | 0.00 | 15.75 | 9.95 | 965.25 | 5,491.22 | |||||||
| Days Payable | 0.00 | 37.02 | 4.28 | 0.00 | ||||||||
| Cash Conversion Cycle | 365.00 | 0.00 | 15.75 | 10.73 | 248.94 | 294.22 | 211.04 | 1,368.03 | 1,420.65 | 7,565.35 | ||
| Working Capital Days | 4,177.22 | 5,069.44 | 25.08 | 29.65 | 148.36 | 234.99 | 530.20 | 4,259.29 | 1,844.93 | 8,551.43 | ||
| ROCE % | -3.00% | -0.61% | -0.60% | -3.17% | 0.47% | 4.01% | -0.53% | -1.31% | -3.93% | -0.79% | -0.13% | -0.40% |
Documents
Announcements
-
Investor Complaints As Per Regulation 13(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
17 Oct - No investor complaints for quarter ended 30 September 2025.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Oct - Dear Sir/Madam, Please find attached the certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants), Regulations, 2018 issued by the Registrar and Share Transfer …
-
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
1 Oct - Scrutinizer report: e-AGM held 30 Sep 2025; all four resolutions passed, 4,14,620 votes tallied.
-
Compliance-57 (5) : intimation after the end of quarter
1 Oct - No non-convertible securities; no payments due for quarter 01-Jul-2025 to 30-Sep-2025.
-
Intimation Under Regulation 57(4) Of SEBI (LODR) Regulations, 2015.
1 Oct - No non-convertible securities with interest/dividend/principal payable in Oct–Dec 2025 quarter.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Alteration in MoA:[1]
In FY22, company altered its main objects of Memorandum of Association and inserted new objects viz.:
a) To manufacture, import, export, wholesale or retail trade all kinds of pharmaceuticals, antibiotics, drugs, medicines, biological, Nutraceutical, healthcare, Ayurveda and dietary supplement products, medicinal preparations, vaccines, chemicals, chemical products, dry salters, mineral waters, wines, cordials, liquors, soups, broths and other restoratives or foods
b) To deal in medicinal goods viz. surgical instruments, contraceptives, photographic goods, oils, perfumes, cosmetics, patent medicines, soaps, artificial limbs, hospital requisites, proprietary medicines, veterinary medicines and tinctures extracts
c) To carry on the business of vialling, bottling, repacking, processing of tablets, capsules, syrups, injections, ointments, etc.
d) To carry on the business of chemists, druggists, buyers, sellers, agents, distributors and stockiest of all kinds of pharmaceuticals and allied products